Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study
- PMID: 15223775
- DOI: 10.1080/01926230490483351
Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study
Abstract
The present study investigated the anti-atherosclerotic activity of lacidipine, a calcium antagonist with antioxidant properties in apoE-deficient mice. These mice show widespread vascular lesions which closely resemble the inflammatory-fibrous plaques seen in humans in atherosclerosis. Mice were fed a Western-type diet (WTD), and treated for 8 weeks with either vehicle or lacidipine at 3 or 10 mg/kg/day. In parallel with histological studies of atherosclerotic lesions in the aorta, functional studies on vascular acetylcholine (ACh) reactivity and analysis of voltammetric levels of nitric oxide (NO) were performed. Recent work has suggested that dihydropyridines (DHPs) modulate vascular relaxation via an increase in the release of NO. Lacidipine treatment had no effect on the plasma lipid profile. However, a significant (p < 0.01) dose-related reduction of 36.4% and 43.3% of the aortic lesion area in respect to methocel-treated mice was observed. Moreover, the aortic ring from control apoE-deficient mice fed a WTD for 8 weeks showed a lower relaxation in response to ACh in comparison to wild-type C57BL/6J mice; on the contrary, lacidipine-treated apoE-deficient mice lacidipine-treated displayed a response similar to that of wildtype C57BL/6J mice. Voltammetric analyses demonstrated a significant decrease of NO release in apoE-deficient mice, while lacidipine-treated mice showed enhanced activity of the NO system. We conclude that lacidipine reduced the extent of atherosclerotic area in hypercholesterolemic apoE-deficient mice, and this reduction may be associated with the capacity of the drug to maintain endothelial NO levels at concentrations useful to protect against vascular damage.
Similar articles
-
The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse.J Hypertens. 2000 Oct;18(10):1429-36. doi: 10.1097/00004872-200018100-00010. J Hypertens. 2000. PMID: 11057430
-
Morphological and functional alterations of the cochlea in apolipoprotein E gene deficient mice.Hear Res. 2005 Oct;208(1-2):54-67. doi: 10.1016/j.heares.2005.05.010. Epub 2005 Jul 26. Hear Res. 2005. PMID: 16051453
-
Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters.Biomed Pharmacother. 2000 Mar;54(2):93-9. doi: 10.1016/S0753-3322(00)88858-7. Biomed Pharmacother. 2000. PMID: 10759293
-
Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.Drugs R D. 2002;3(5):311-23. doi: 10.2165/00126839-200203050-00005. Drugs R D. 2002. PMID: 12455152 Review.
-
The antiatherosclerotic effects of calcium antagonists.J Cardiovasc Pharmacol. 1995;25 Suppl 3:S6-10. J Cardiovasc Pharmacol. 1995. PMID: 8852538 Review.
Cited by
-
Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.Vascul Pharmacol. 2010 Nov-Dec;53(5-6):193-9. doi: 10.1016/j.vph.2010.08.003. Epub 2010 Aug 12. Vascul Pharmacol. 2010. PMID: 20709189 Free PMC article.
-
Oral Therapy with Amlodipine and Lacidipine, 1,4-Dihydropyridine Derivatives Showing Activity against Experimental Visceral Leishmaniasis.Antimicrob Agents Chemother. 2008 Jan;52(1):374-7. doi: 10.1128/AAC.00522-07. Epub 2007 Oct 22. Antimicrob Agents Chemother. 2008. PMID: 17954702 Free PMC article.
-
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.Oxid Med Cell Longev. 2016;2016:1892412. doi: 10.1155/2016/1892412. Epub 2016 Jan 6. Oxid Med Cell Longev. 2016. PMID: 26881016 Free PMC article. Review.
-
Calcium channel blockers increase the amount of nitrite production in rabbits without decreasing the responsiveness of platelets to collagen.Clin Exp Med. 2007 Dec;7(4):142-8. doi: 10.1007/s10238-007-0138-7. Epub 2008 Jan 11. Clin Exp Med. 2007. PMID: 18188526
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous